Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
TM
The BV Droplets Down Under: From Model Emulsions to Drug Delivery
Clive Prestidge
Ian Wark Research Institute,The ARC Special Research Centre for Particle and Material Interfaces,
University of South Australia,
Memories of those good old days at Bristol in the late 80’s with Brian as your supervisor
Civilised with a high level of decorum
BV’s Balls
Non-Cross linked Droplets:Viscous & deformable
(η < 5 mNm-2s)
NH3 NH3
OEtEtO
CH3
Si
CH3
Cross linked droplets Deformability control:viscous to viscoelastic
OEtEtO
OEt
Si
CH3
- Highly monodispersed (~1μm in diameter)
- Emulsifier free, negatively charged with IEP ≈ pH 2.5
T. M. Obey & B. Vincent, J. Colloid Interface Sci., 163 (1994) 454.M. I. Goller et al., Colloids Surf. A:, 123-124 (1997) 183.
T. M. Obey & B. Vincent, J. Colloid Interface Sci., 163 (1994) 454.M. I. Goller et al., Colloids Surf. A:, 123-124 (1997) 183.
BV’s PDMS Droplets
The BV Droplets – an excellent model colloid with controllable deformability
Interaction forces of the BV droplets
Rheological studies on concentrated emulsions of the BV droplets
Block copolymers at the BV droplet - water interface
Nanoparticles at the BV droplet - water interface
Molecular transport across the BV droplet - water interface.
Do the BV Balls Squash?Deformable BV droplets are more colloidally stable
0
50
100
150
200
250
300
4 6 8 10pH
ccc
(mM
)
Cross-linked droplets
Liquid droplets
Potential from PDPotential from PD
Deflection of cantileverDeflection of cantilever
Interdroplet forcesInterdroplet forces
F = – kc xF = – kc xkc: spring constant of cantileverkc: spring constant of cantileverx : deflection of cantileverx : deflection of cantilever
Hooke’s LawHooke’s Law
PhotodiodePhotodiode
CantileverCantileverProbeProbe
TargetTarget
LaserLaser
Interaction forces on the BV droplets determined using colloid probe atomic force
microscopy (AFM)
00Forc
eFo
rce
Drive distanceDrive distanceAABBCCDD
AA BB CC DD AA BB CC DD
DeformableDeformable
NondeformableNondeformable
(Def
lect
ion)
(Def
lect
ion)
Approach Rate DependenceApproach Rate Dependence
Low rateLow rate
Forc
eFo
rce
Drive distanceDrive distance
High rateHigh rate
Forc
eFo
rce
Drive distanceDrive distance
-12
-10
-8
-6
0 50 100 150 200 250
Arbitrary Separation (nm)
ln (F
orce
/2πR
)
-12-11-10
-9-8
200 210 220 230 240
50% ( ), 45% (▲), 40% (■), 35% (▲), 30% (•).
Interaction Forces between BV Droplets and AFM colloid probe Interaction Forces between BV Droplets and AFM colloid probe
Gillies and Prestidge, Langmuir, 21, 12342-12347, 2005
-0.5
0
0.5
1
1.5
2
2.5
3
-150 -100 -50 0 50
Nominal Separation (nm)
Forc
e/2 π
R (m
N/m
)
50% ( ), 45% (▲), 40% (■), 35% (▲), 30% (•).
Deformation & Deformation & HysteresisHysteresis-- influence of crossinfluence of cross--linking:linking:
Gillies and Prestidge, Langmuir, 21, 12342-12347, 2005
0
0.01
0.02
0.03
0.04
0.05
-100 -50 0 50
Nominal Separation (nm)
Forc
e/2 π
R (m
N/m
)Liquid-like BV Droplets:
Influence of Surfactant (SDS)( ) No SDS ( )10-4M ( )10-3M ( )10-2M
RPDMS = 10 μm
GS Gillies, CA Prestidge, Adv. Colloid Interface Sci, 108-109, 197-205, 2004.
Spring constant controlled by interfacial tension
0123456789
0 5 10 15 20
Interfacial Tension (mN/m)
Sprin
g C
onst
ant (
mN
/m) No SDS
10 -4M SDS
10 -2M SDS
10 -3M SDS
RPDMS = 10 μm
GS Gillies, CA Prestidge, Adv. Colloid Interface Sci, 108-109, 197-205, 2004.
Laplace pressure controls spring constant
0
10
20
30
40
50
0 0.5 1 1.5 21/Radius (μm-1)
Sprin
g C
onst
ant (
mN
/m)
Liquid-like BV Droplets: Influence of size
GS Gillies, CA Prestidge, Adv. Colloid Interface Sci, 108-109, 197-205, 2004.
-0.50
0.5
1.5
2.5
3.5
-70 -50 -30 -10 10 30 50Nominal Separation (nm)
Forc
e/2π
R (m
N/m
)
Cross-linked BV Droplets: Approach Rate Dependence
Slow (0.25 μm/s)
Fast (4 μm/s)
Gillies and Prestidge, Langmuir, 21, 12342-12347, 2005
Cross-linked BV Droplets: Load Dependence
-1
1
3
5
7
-90 -40 10
Nominal Separation (nm)
Forc
e/2 π
R (m
N/m
)
Approach rate = 1 μm/s
Nano-Rheology of a BV Droplet
ViscoelasticityViscoelasticity of a Sphere (Attard, of a Sphere (Attard, Phys. Rev. E,Phys. Rev. E, 2001)2001)
( )τ/
0
011 teEE
EEEtE
−
∞
∞
∞
−+=
E0 = 1.2 MPa, E∞ = 0.8 MPa and τ = 0.12 s
-0.5
0.5
1.5
2.5
3.5
-100 -50 0 50Nominal Separation (nm)
Forc
e/2 π
R (m
N/m
)
0.25 0.25 μμm/sm/s
1 1 μμm/sm/s
1 1 μμm/s (low load)m/s (low load)
Gillies and Prestidge, Langmuir, 21, 12342-12347, 2005
Rheological studies on concentrated emulsions of the BV droplets
Shear RateShear Rate
Shea
r Vis
cosi
tySh
ear V
isco
sity
3D Network3D Network
LayersLayers
CompressionCompression
“Order-Disorder”Transition
“Order-Disorder”Transition
ClustersClustersSuspensionsSuspensions
EmulsionsEmulsions
1
10
100
1000
0 10 20 30 40 50 60 70 80
Viscosity versus volume fractionViscosity versus volume fraction
Volume Fraction / %Volume Fraction / %
Rel
ativ
e V
isco
sity
Rel
ativ
e V
isco
sity
SilicaSilicaBV droplets (cross linked)BV droplets (cross linked)BV droplets (liquid)BV droplets (liquid)
Krieger-DoughertyHard spheresKrieger-DoughertyHard spheres
Saiki, Prestidge and Horn, Colloids and Surfaces A, 299, 65-72, 2006.
0.00.51.01.52.02.53.03.54.0
0 20 40 60 80 100Ceq (ppm)
Ads
orbe
d Amt (m
g m
-2)
0.00.51.01.52.02.53.03.54.0
0 20 40 60 80 100Ceq (ppm)
Ads
orbe
d Amt (m
g m
-2)
0.00.51.01.52.02.53.03.54.0
0 20 40 60 80 100Ceq (ppm)
Ads
orbe
d Amt (m
g m
-2)
0.00.51.01.52.02.53.03.54.0
0 20 40 60 80 100Ceq (ppm)
Ads
orbe
d Amt (m
g m
-2)
Adsorbed Amount of F108
Silica
Polystyrene latex
Cross-linked droplets
Liquid droplets
Prestidge, Barnes and Simovic, Adv. Colloid Interface Sci , 108-109, 105-118, 2004.
0
5
10
15
20
25
0 20 40 60 80 100Concentration (ppm)
Thickn
ess (nm)
0
5
10
15
20
25
0 20 40 60 80 100Concentration (ppm)
Thickn
ess (nm)
0
5
10
15
20
25
0 20 40 60 80 100Concentration (ppm)
Thickn
ess (nm)
0
5
10
15
20
25
0 20 40 60 80 100Concentration (ppm)
Thickn
ess (nm)
Adsorbed Layer Thickness of F108
Silica
Polystyrene latex
Cross-linked droplets
Liquid droplets
Prestidge, Barnes and Simovic, Adv. Colloid Interface Sci , 108-109, 105-118, 2004.
0
100
200
300
400
500
0 0.5 1Surface Coverage
ccc
(mM
)
0
100
200
300
400
500
0 0.5 1Surface Coverage
ccc
(mM
)
Hydrophilic
Hydrophobic
Nanoparticles at the BV droplet - water interface
Simovic and Prestidge, Langmuir, 20, 8357-8365, 2004.
Adsorption of hydrophilic silica nanoparticles to Droplets
Simovic & Prestidge, Langmuir 19 (2003) 3785-3790
0
50
100
150
200
250
0 0.2 0.4 0.6Equilibrium concentration (wt%)
Ads
orbe
d a
mou
nt
(mgm
-2)
♦10-3 M NaCl; ■ 10-2 M NaCl; ▲10-1 M NaCl
h = a (1/θ1/2 –1) h- lateral separationa-particle diameterθ-plateau fraction
coverage
Simovic & Prestidge, Langmuir 19 (2003) 8364-8370
Adsorption of hydrophobic silica nanoparticles (10-4 M NaCl)pH: ♦ 9; ▲ 7; ■ 5; ● 4
0
200
400
600
800
1000
1200
0 0.1 0.2 0.3 0.4 0.5Equilibrium concentration (wt%)
Ads
orbe
d am
ount
(mgm
-2)
050
100150200250
0 0.1 0.2
Liquid BV Droplets Cross-linked BV Droplets
Multilayer adsorptionStrong pH dependencyAdsorption affinity is greater for liquid droplets
Simovic & Prestidge, Langmuir 19 (2003) 8364-8370
Adsorption of hydrophobic silica nanoparticles (10-4 M NaCl)pH: ♦ 9; ▲ 7; ■ 5; ● 4
0
200
400
600
800
1000
1200
0 0.1 0.2 0.3 0.4 0.5Equilibrium concentration (wt%)
Ads
orbe
d am
ount
(mgm
-2)
050
100150200250
0 0.1 0.2
0
100
200
300
400
500
0 0.1 0.2 0.3 0.4 0.5Equilibrium concentration (wt%)
Adso
rbed
am
ount
(mgm
-2)
0
50
100
0 0.1 0.2
Dibutyl phthlate (DBP)
USP rotating paddle method+ ultracentrifugation + HPLC analysis
Molecular transport across the BV Molecular transport across the BV dropletdroplet--water interfacewater interface
DBL release from BV Droplets: low loading levels – 0.28mg/100ml
0
0.05
0.1
0.15
0.2
0.25
0.3
0 2000 4000
Time (min.)
DB
P re
leas
ed (m
g/10
0ml) bare PDMS droplets
hydrophobic nanoparticle coatings
~580 kJmol-1
Activation Energy
Pluronic F-68 Activation energy for release = 52.8 kJmol-1
Washington et al. J. Controlled Release 33 (1995) 383-390
Prestidge & Simovic: Int. J. Pharmaceutics, 324, 92-100, 2006.European J. of Pharmaceutics and Biopharmaceutics, 66, 39-47 2007
bare BV Droplets
hydrophilic
Nanoparticle coatings:
DBL release from BV Droplets: high loading levels – 2.8mg/100ml
0
0.5
1
1.52
2.5
3
3.5
0 2 4 6 8
Time (h)
Amou
nt re
leas
ed (m
g/10
0ml)
Prestidge & Simovic: Int. J. Pharmaceutics, 324, 92-100, 2006.European J. of Pharmaceutics and Biopharmaceutics, 66, 39-47 2007
hydrophobic
1. Drug incorporation into lipid vehicle
Vehicle (oil droplet)
2. Vehicle encapsulation by nanoparticles
Wet coated droplet
3. Vehicle drying
4. Vehicle redispersion Dry coated
droplets (for storage)
Hydrophilic silica Hydrophilic silica nanoparticlesnanoparticles
(~ 50 nm)(~ 50 nm)
Lipophilicdrug
DermalDelivery
OralDelivery
Towards Drug DeliveryTowards Drug Delivery
Improved Photo-stability of Vitamin A in Nanoparticle Coated Emulsions
26.220.18Nanoparticlecoating B
5.270.91Nanoparticlecoating A
0.3713.10Control Emulsion
t1/2 (day)k, min -1(×104)Formulation
All-trans Vitamin A 9-cis Vitamin A(Biopotency: 100%) (Biopotency: 24% )
UV lightIsomerisation
N. Ghouchi Eskandar, S. Simovic and C. A. Prestidge, Phys ChemChem Phys, 9 (48), 6426-6434, 2007.
Dry capsules for oral delivery:
Spray dryingFreeze-dryingPhase coacervation
Drying method + formulation composition controls:
StructureStabilityDelivery characteristics
In vivo studies:
Increased bioavailability
Faster action
improved oral delivery of poorly soluble drugs,
e.g.indomethicin
0
2
4
6
8
10
12
14
0 5 10 15 20Time(h)
Con
.C(u
g/m
l) Lipoceramic capsule
Drug suspension
COOHCH2
Me O
Me
Cl
O
N
In vivo Bioavailability of Celecoxib
Emulsion 2Emulsion 1
Miglyol Oil
Aq susp.
Capsule 2Capsule 3
Capsule 1
Celebrex
In-vitro / In-vivo Correlation
0
20
40
60
80
100
120
0 20 40 60 80 100
% of dissolved drug after 15 min.
Bioa
vaila
bilit
y (%
)
Celecoxib
Celebrex
Lipoceramic Capsules
Concluding Remarks
BVBV’’s s monodispersedmonodispersed silicone emulsions are an excellent silicone emulsions are an excellent model colloidmodel colloid
Investigations of the BV droplets have improved Investigations of the BV droplets have improved understanding of emulsion interfacesunderstanding of emulsion interfaces
The BV droplets have inspired the development of new drug delivery systems based on emulsions and nanoparticles
Dr Graeme Gillies (AFM studies)Dr Graeme Gillies (AFM studies)
Dr Yasushi Saiki (rheology Dr Yasushi Saiki (rheology studies)studies)
Dr Tim Barnes (polymer Dr Tim Barnes (polymer interaction)interaction)
Dr Spomenka Simovic Dr Spomenka Simovic ((nanoparticlenanoparticle interaction)interaction)
Angel Tan (oral delivery)Angel Tan (oral delivery)
Nasrin Eskandar (dermal Nasrin Eskandar (dermal delivery)delivery)
AcknowledgementsAcknowledgements
Nano-structured Drug Delivery Systems at the Wark
Liposomes
Emulsions + Micro/NanoCapsules
Nanoparticles
MesoporousParticles
DNA-lipids
Dendrimers
Drug encapsulation
Formulation stability
Controlled release
Improving bioavailability
Controlled circulation
Targeted delivery
Functional Nanoparticle Research at the WarkTM: Towards a new generation of diagnostic and
therapeutic nanomaterials.
Initial interfacial coverage in the range 0.7 and 0.9: chain structures
45 min. 2h
Hydrophobic nanoparticles: restricted (limited) coalescence
Initial interfacial coverage of hydrophobic nanoparticlesof ~0.6: dendritic structures
Simovic & Prestidge: Langmuir 20, 8357, 2004
log (time)
E(t)
Data Analysis: Nano-RheologyViscoelasticityViscoelasticity of a Sphere (Attard, of a Sphere (Attard, Phys. Rev. E,Phys. Rev. E, 2001)2001)
Long time-scale Modulus E∞
Short time-scale Modulus E0
( )τ/
0
011 teEE
EEEtE
−
∞
∞
∞
−+=
τ
Bioavailability
L-Maltodex.
L-bare droplets
Pure celecoxib
susp.
CELEBREXOil disp.
50
60
70
80
90
100
110
120
Celecoxib formulations
Absolute F (%)
Bare liquid systems Redispersed dry capsules
(n ≥ 3; One-way ANOVA: p < 0.1 )
®
L-S(aq)L-S(aq,oil)
Cmax (μg/ml) Tmax (min)
Oil disp.
CELEBREX
Pure celecoxib
susp.
L-bare droplets
L-Maltodex.
L-Si(aq)
L-Si(aq+oil)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Celecoxib formulations
L-Si(aq+oil)
L-Si(aq)L-Maltodex.
L-bare droplets
Pure celecoxib
susp.
CELEBREX
Oil disp.
0
60
120
180
240
300
360
420
Celecoxib formulations
p<0.01 p<0.05
Model Drug: Celecoxib (BCS Class II drug)
Indications: Anti-inflammatory drug
primarily for rheumatoid arthritis & osteoarthritis
Difficult processing into solid dosage forms (tablets)
► Cohesiveness; Low bulk density & compressibility; Poor flow properties
Slow onset of action (pain relieving)► High Tmax (3 h)
Incomplete & variable absorption; Excessive dose-dumping; No liquid formulation exists
► Hydrophobic (log P ≈ 3.5)► Low solubility (7 µg/ml)
Pharmaceutical limitationsCelecoxib properties
Subject: fasted male Sprague-Dawley rats
Capsule B
Capsule C
Capsule A
Celecoxib Pharmacokinetics: Bioavailability in Orally Dosed Rats
Ex-vivo delivery of Vitamin A to abdominal pig skin:Nanoparticle coatings facilitate better skin delivery from emulsions
-10
-9
-8
-7
-6
-5
0 20 40 60 80 100
Arbitrary Separation (nm)
Ln
(For
ce/2π R
)
CrosslinkedCrosslinked BV Droplets and a Silica SphereBV Droplets and a Silica Sphere
hard spherehard spherebehaviourbehaviour
P(h)=P0e-κh
h
Δh
∼Δh